WSEAS Transactions on Systems and Control
Print ISSN: 1991-8763, E-ISSN: 2224-2856
Volume 21, 2026
Integrating Pharmacometrics and Machine Learning for Enhanced Clinical Trial Outcomes
Authors: , ,
Search Articles
Abstract: A novel computational framework that integrates the mechanistic rigor of Pharmacometrics (PMx)
with the predictive power of Multimodal Machine Learning (MML) is conceptually formulated and discussed.
The framework is designed to address critical developmental bottlenecks in the drug development sector, which
is already witnessing a paradigm shift driven by the rise of Antibody-Drug Conjugates (ADCs)—a class that,
according to recent pipeline analyses, accounts for an expanding share of innovative oncology trials.
Unfortunately, despite the therapeutic promise of ADCs and other targeted modalities, the industry faces a
productivity paradox, characterized by high attrition rates in transitional clinical phases and a median
development timeline of seven years. By leveraging transfer learning strategies, we delineate how the
synergistic adoption of PMx and MML can conceptually optimize dose selection, inform metastatic risk
assessment through genomic-imaging integration, and ultimately accelerate the transition from bench to
bedside. This is conceptualized through the definition of methodologies capable of transforming noisy
early-phase clinical data into actionable insights, thus bridging the gap between Physiologically Based
Pharmacokinetic (PBPK) modeling and deep learning-driven outcomes. Without advancing premature empirical
claims, we establish a structured methodological roadmap for a scalable, AI-enhanced clinical trial
infrastructure, positioning hybrid modeling as a viable architectural paradigm for the next generation of
precision oncology.
Keywords:
Antibody-Drug Conjugates, Pharmacometrics, Machine Learning, Transfer Learning, Clinical
Trial Optimization, Hybrid Modeling, Precision Oncology
Pages: 533-540
DOI: 10.37394/23203.2026.21.46